Bibliografie

Detailansicht

Phosphodiesterases and Their Inhibitors

Methods and Principles in Medicinal Chemistry 61
Wiley-VCH GmbH
ISBN/EAN: 9783527332199
Umbreit-Nr.: 5985816

Sprache: Englisch
Umfang: 240 S., 200 s/w Illustr., 20 farbige Illustr., 220
Format in cm:
Einband: gebundenes Buch

Erschienen am 23.04.2014
Auflage: 1/2014
€ 159,00
(inklusive MwSt.)
Lieferbar innerhalb 1 - 2 Wochen
Beim Buchhandel bestellen
  • Zusatztext

    • Written by the pioneers of Viagra, the first blockbuster PDE inhibitor drug. Beginning with a review of the first wave of phosphodiesterase (PDE) inhibitors, this book focuses on new and emerging PDE targets and their inhibitors. Drug development options for all major human PDE families are discussed and cover diverse therapeutic fields, such as neurological/psychiatric, cardiovascular/metabolic, pain, and allergy/respiratory diseases. Finally, emerging chemotherapeutic applications of PDE inhibitors against malaria and other tropical diseases are discussed.

  • Kurztext

    • Written by the pioneers of Viagra, the first blockbuster PDE inhibitor drug. Beginning with an overview of the current status of research into phosphodiesterase (PDE) inhibitors, this book focuses on new and emerging PDE targets and their inhibitors. Drug development options for all major human PDE families are discussed and cover diverse therapeutic fields, such as neurological/psychiatric, cardiovascular/ metabolic, pain, and allergy/respiratory diseases. Separate chapters describe the impact of structural biology on the development of selective inhibitors. Finally, emerging chemotherapeutic applications of PDE inhibitors against malaria and other tropical diseases are discussed.

  • Autorenportrait
    • Spiros Liras is the head of the cardiovascular metabolic and endocrine diseases (CVMED) medicinal chemistry department at Pfizer R&D in Groton (USA). Previously, he was Senior Director of medicinal chemistry in Neuroscience at Pfizer, working on treatments for addiction, depression, schizophrenia, cognition and Alzheimer's disease. Dr. Liras obtained a Ph.D. in organic chemistry in 1989 from Iowa State University. Subsequently, he joined the group of Professor Stephen F. Martin at the University of Texas at Austin as a postdoctoral fellow. He is the author or coauthor of more than 50 publications and patents. Andrew Bell has been with Pfizer for over 30 years, following studies at York University (UK). He spent the first 9 years of his career working on PDE inhibitors leading to the inotrope/vasodilator (PDE3) candidate, nanterinone, and the PDE5 inhibitor, sildenafil (Viagra, Revatio). Soon after the discovery of sildenafil in 1989, he moved to antifungals research until 1999, when he was given responsibility for File Enrichment, as part of Pfizer's collaborations with ArQule and Tripos. He has subsequently been working in the hit-to-lead arena in Pfizer's Sandwich and Groton Laboratories, making use of the File Enrichment investment to generate new lead series for multiple projects, including novel series of selective PDE inhibitors. Dr. Bell was awarded one of the 2008 Awards for Technical Achievements in Organic Chemistry by the American Chemical Society.